siRNA acts upstream of disease-driving proteins by degrading target mRNA. Amphorna Biosciences builds on this biology with targeted delivery, modular RNA design, and cell-specific entry to address fibrosis biology, immune-related diseases, and difficult oncology targets.
Fibrosis-related ligands or tumor- and immune-antigen binding domains guide RNA payloads toward disease-relevant cells.
RNA payloads are released intracellularly to act on targeted molecular pathways.
RISC-mediated mRNA degradation can reduce the production of proteins linked to fibrosis progression, immune-related diseases, or cancer growth.
Rationally engineered siRNA sequences optimized for potency, stability, and reduced off-target effects.
Lipid nanoparticles engineered with fibrosis-related targeting ligands to reach fibroblast-rich tissue beyond the liver.
AOC constructs pair tumor- or immune-targeting antibodies with RNA payloads for precise delivery to disease-relevant cells.